Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 0.00 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 326 to 348 of 475 messages
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
DateSubjectAuthorDiscuss
07/9/2018
07:48
Is it "post something completely irrelevant" day ?
dexdringle
07/9/2018
07:40
htTps://twitter.com/Stockonomist/status/1037963927072788480?s=19
the stigologist
05/9/2018
15:39
"Crazy low valuation".....well only if the science works. Otherwise it is worth £0.....
dexdringle
03/9/2018
10:44
Crazy low valuation I still expect deal to be viewed positively in North America so the existing discount will simply become bigger and bigger
the stigologist
29/8/2018
00:36
hTtp://www.stockhouse.com/news/press-releases/2018/08/28/portage-provides-update-on-proposed-acquisition-of-salvarx
the stigologist
29/8/2018
00:35
Update re proposed disposal and demerger Further to the announcement of 14 August 2018 relating to the proposed disposal of the Company's 94.2 per cent. interest in its subsidiary SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company has been informed that the Portage shareholder circular has now been submitted to the Canadian Securities Exchange ("CSE") for review. Following completion of the CSE review, both Portage and the Company will publish their respective shareholder circulars and a further announcement will be made by the Company.
the stigologist
27/8/2018
08:14
If a startup company can be valued at $10 billion on just 40 patients data the potential for Intensity to be a $1 billion dollar company in the near future can't be dismissed. The Insiders clearly think we are onto something massive.
the stigologist
27/8/2018
08:12
These are mind boggling numbers... " The investor community is also optimistic about this sector with record amounts of venture money flowing into startups this past year. In fact, in February 2018, BMS recorded the largest upfront payment for a license in history. They paid US$3.6 billion for 35% of the profits on Nektar's immunotherapy after seeing data on approximately 40 patients."
the stigologist
26/8/2018
11:46
One does get the impression that ducks are being lined up in a row. Fig.
fig1
26/8/2018
10:30
Agree Stig. Intensity hasn’t tweeted since Dec 2017, now they tweet every day. Take the hint
jonesyboy 27
26/8/2018
01:03
In 5 years Intensity only ever tweeted 200 times up to August 20th (about 40 tweets a year, less than one a week) In the last week Intensity have tweeted about 10 tweets, including retweeting a tweet mentioning #SALV and they've hinted their next major Presentation of Data is due in October... The writing is pretty much on the wall for anybody with more than one braincell. SALV / Portage clean up September Intensity results October Intensity will be looking like a $1bn+ company SALV/Portage investors are going to clean up bigtime Mellon etc aren't in this for a minor £m here or there, they're going for the big one £100m+
the stigologist
26/8/2018
00:31
Great consolidation expect 100p+ soon
the stigologist
23/8/2018
09:34
Jonesy, Thanks for confirming Portage will be under the complete control of Mellon and Bailey. The shell will be able to sell Portage to pay off debt, admin costs with a bit of cash left over. It will need to do an RTO within 12 months (6 months before suspension and then 6 months until the listing is cancelled). Unless Eke has something lined up, and he may have one of his own businesses, that is quite a racy timeline given all the bureaucracy involved. Https://beta.companieshouse.gov.uk/officers/FXm-TSe6fKwCqaT3axE0iKP1SRQ/appointments Https://beta.companieshouse.gov.uk/officers/luGUWHkdxSTf3WWinrekk4ocTsQ/appointments Https://beta.companieshouse.gov.uk/officers/NuPbTd4OpHw9afEgQUUyJvRMz54/appointments Https://beta.companieshouse.gov.uk/officers/TxwouW_JrpHJOHXDpiwQk4uDdiA/appointments Https://beta.companieshouse.gov.uk/officers/Su6PT0JB0tBzDoYHJQJbVkNVLKY/appointments Https://beta.companieshouse.gov.uk/officers/009G8Gh1GpR45GPYOsbBlkSvuSI/appointments
sweet karolina
22/8/2018
17:14
Mellon & Bailey hold 40% portage pre-deal and will hold ~60% of portage post deal. With the Salv shell waiting with 60 million + portage shares. What will they use the shell for is the question....
jonesyboy 27
22/8/2018
13:40
Cudmore. Clown who posts on wrong thread. Filtered.
dexdringle
22/8/2018
12:43
As I said earlier!! IIP! https://twitter.com/nictrades/status/1032244070175911937?s=21
cudmore
22/8/2018
08:53
IIP about to take off. 30p short term easily here.
cudmore
22/8/2018
07:27
That is the problem with many new drugs, they pass stage 1, which shows they do no harm, they many get part way through stage 2 showing some benefits, but when they go up against existing drugs they often fail to show a clear efficacy advantage. Even then commercial success is not guaranteed as it all depends on whether NHS / Insurance companies are prepared to pay the extra for them. It will be interesting to read the valuation report, which gives a range of values using a variety of techniques, ultimately though it is a lot like waiting to see if your numbers come up in the lottery. I expect the valuation report will be made available here: Https://www.portagebiotech.com/investors/shareholder-circular.html
sweet karolina
22/8/2018
07:18
Also Dex, before we get ahead of ourselves, there is competition... https://dailym.ai/2Bu6RO4
fig1
22/8/2018
06:59
Good god. What did they say in the prior tweet that could possibly have left the door open to that interpretation such that a clarification was necessary ? Summary: Tweet one - good news a patient has survived six years using drugs Tweet two - just to be clear, they weren't our drugs, they were someone else's drugs that are clearly working thus rendering our drugs potentially redundant Great. Well done.
dexdringle
21/8/2018
21:20
This is a nice story but I hope the person responsible for tweeting at Intensity leaves out the whimsy and sticks to facts pertaining to relevant trials. This is just damaging potentially. https://twitter.com/IntensityInc/status/1031993192349032448?s=19
fig1
21/8/2018
16:26
About to take off soon. Doing a deal when it's quiet in August. Expect big news and interest during September. I can see Portage shares doing very well as those who benefited from the $200m+ pay out previously realise these guys are going for a repeat if not a bigger better deal having demonstrated their understanding of this sector before
the stigologist
21/8/2018
15:18
Oh, there we go. Pressure building.....
fig1
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191114 06:24:52